CTNS mutations in African American patients with cystinosis

被引:27
作者
Kleta, R
Anikster, Y
Lucero, C
Shotelersuk, V
Huizing, M
Bernardini, I
Park, M
Thoene, J
Schneider, J
Gahl, WA
机构
[1] NICHHD, Sect Human Biochem Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA
[2] Tulane Univ, Sch Med, Hayward Genet Ctr, New Orleans, LA 70112 USA
[3] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA
关键词
ocular cystinosis; splicing; mutation analysis; African American;
D O I
10.1006/mgme.2001.3218
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cystinosis, an autosomal recessive lysosomal storage disorder, is rarely diagnosed in African Americans. The disease results from mutations in the gene CTNS; at least 55 such mutations have been reported. By far the most common is a 57,257-bp deletion of Northern European origin encompassing most of the CTNS gene. We performed mutation analysis on DNA from four African American patients with cystinosis. In one individual with classical, nephropathic cystinosis, we identified a new molecular defect, i.e., a homozygous GT-->CC substitution at the +5 position of IVS 5 of CTNS (IVS 5+5 GT-->CC). The out-of-frame splicing of exon 5 creates a null allele consistent with the patient's severe phenotype. Two patients were heterozygous and one homozygous for the common 57-kb deletion allele, reflecting the admixture of African and Northern European gene pools in North America. The two African Americans heterozygous for the 57-kb deletion were also hemizygous for a 928G-->A change, associated with ocular or nonnephropathic cystinosis. These two individuals are the only known African Americans with ocular cystinosis. We conclude that the diagnosis of cystinosis should be entertained in African Americans with symptoms of the disease, and that mutation analysis for the 57-kb deletion should be considered in this group of patients. (C) 2001 Academic Press.
引用
收藏
页码:332 / 337
页数:6
相关论文
共 37 条
[21]  
JONAS AJ, 1982, JOHNS HOPKINS MED J, V151, P117
[22]   REMOVAL OF CORNEAL CRYSTALS BY TOPICAL CYSTEAMINE IN NEPHROPATHIC CYSTINOSIS [J].
KAISERKUPFER, MI ;
FUJIKAWA, L ;
KUWABARA, T ;
JAIN, S ;
GAHL, WA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (13) :775-779
[23]   A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CYSTEAMINE EYE DROPS IN NEPHROPATHIC CYSTINOSIS [J].
KAISERKUPFER, MI ;
GAZZO, MA ;
DATILES, MB ;
CARUSO, RC ;
KUEHL, EM ;
GAHL, WA .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (05) :689-693
[24]  
KRASNEWICH DM, 1991, ENDOCRINOLOGIST, V1, P111
[25]   IMPROVED RENAL-FUNCTION IN CHILDREN WITH CYSTINOSIS TREATED WITH CYSTEAMINE [J].
MARKELLO, TC ;
BERNARDINI, IM ;
GAHL, WA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (16) :1157-1162
[26]   LINKAGE OF THE GENE FOR CYSTINOSIS TO MARKERS ON THE SHORT ARM OF CHROMOSOME-17 [J].
MCDOWELL, GA ;
GAHL, WA ;
STEPHENSON, LA ;
SCHNEIDER, JA ;
WEISSENBACH, J ;
POLYMEROPOULOS, MH ;
TOWN, MM ;
VANTHOFF, W ;
FARRALL, M ;
MATHEW, CG .
NATURE GENETICS, 1995, 10 (02) :246-248
[27]   Molecular analysis of cystinosis: Probable Irish origin of the most common French Canadian mutation [J].
McGowan-Jordan, J ;
Stoddard, K ;
Podolsky, L ;
Orrbine, E ;
McLaine, P ;
Town, M ;
Goodyer, P ;
MacKenzie, A ;
Heick, H .
EUROPEAN JOURNAL OF HUMAN GENETICS, 1999, 7 (06) :671-678
[28]  
PETERSEN EM, 1984, S AFR MED J, V66, P44
[29]  
PISONI RL, 1985, J BIOL CHEM, V260, P4791
[30]  
Sambrook J., 2002, MOL CLONING LAB MANU